Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 14CNS 3Gynecologic 1

Conditions

Brain Neoplasms 3Disease 2

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × fluciclovine F-18 × CNS × Clear all
NCT04410133 2025-08-28

REVELATE

Blue Earth Diagnostics

Phase 3 Completed
151 enrolled 29 charts
CNS

Brain Neoplasms, Disease

NCT04410367 2025-07-20

PURSUE

Blue Earth Diagnostics

Phase 2 Completed
23 enrolled 10 charts
CNS

Brain Neoplasms, Disease

NCT03276676 2024-12-27

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

University of Utah

Phase 1/2 Terminated
10 enrolled 7 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡